{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:48Z","timestamp":1793832468105,"version":"4.6.1"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group listed 15 topics of concrete clinical scenarios and formulated as practical answers as possible based on available evidence. The 15 topics are: (1) Practical start-up and follow-up scheme for patients on NOACs; (2) How to measure the anticoagulant effect of NOACs; (3) Drug\u2013drug interactions and pharmacokinetics of NOACs; (4) Switching between anticoagulant regimens; (5) Ensuring compliance of NOAC intake; (6) How to deal with dosing errors; (7) Patients with chronic kidney disease; (8) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a risk of bleeding? (9) Management of bleeding complications; (10) Patients undergoing a planned surgical intervention or ablation; (11) Patients undergoing an urgent surgical intervention; (12) Patients with AF and coronary artery disease; (13) Cardioversion in a NOAC-treated patient; (14) Patients presenting with acute stroke while on NOACs; (15) NOACs vs. VKAs in AF patients with a malignancy. Since new information is becoming available at a rapid pace, an EHRA Web site with the latest updated information accompanies this text (www.NOACforAF.eu).<\/jats:p>","DOI":"10.1093\/europace\/eut083","type":"journal-article","created":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T12:39:51Z","timestamp":1366979991000},"page":"625-651","source":"Crossref","is-referenced-by-count":612,"title":["European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation"],"prefix":"10.1093","volume":"15","author":[{"given":"Hein","family":"Heidbuchel","sequence":"first","affiliation":[{"name":"University Hospital Gasthuisberg 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]},{"name":"University of Leuven 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[{"name":"University Hospital Gasthuisberg 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]},{"name":"University of Leuven 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alings","sequence":"additional","affiliation":[{"name":"Amphia Ziekenhuis 2 Department of Cardiology , , Breda ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Antz","sequence":"additional","affiliation":[{"name":"Klinikum Oldenburg 3 Department of Cardiology , , Oldenburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[{"name":"Ruprecht Karls Universit\u00e4t 4 Department of Neurology , , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala University 5 Uppsala Clinical Research Center and Dept of Medical Sciences , , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sinnaeve","sequence":"additional","affiliation":[{"name":"University Hospital Gasthuisberg 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]},{"name":"University of Leuven 1 Department of Cardiovascular Medicine , , , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[{"name":"St George's University 6 Clinical Cardiology , , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"University of Birmingham Centre for Cardiovascular Sciences 7 , Birmingham ,","place":["UK"]},{"name":"University of M\u00fcnster 8 Department of Cardiology and Angiology , ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,1]]},"reference":[{"key":"2026081001075813400_EUT083C1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"2026081001075813400_EUT083C2","first-page":"1385","article-title":"Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"2026081001075813400_EUT083C3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"2026081001075813400_EUT083C6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C7","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehs071","article-title":"Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation","volume":"33","author":"Hendriks","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht096","article-title":"A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice","author":"Berti","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2026081001075813400_EUT083C11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2011.10.017","article-title":"Interpretation of point-of-care INR results in patients treated with dabigatran","volume":"125","author":"van Ryn","year":"2012","journal-title":"Am. J. Med."},{"key":"2026081001075813400_EUT083C12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"2026081001075813400_EUT083C13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026081001075813400_EUT083C14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"key":"2026081001075813400_EUT083C15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb and haemost"},{"key":"2026081001075813400_EUT083C16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026081001075813400_EUT083C17","first-page":"S2","article-title":"Absolute bioavailability of edoxaban in healthy subjects","volume":"13","author":"Matsushima","year":"2011","journal-title":"AAPS J"},{"key":"2026081001075813400_EUT083C18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos, Biol Fate Chem"},{"key":"2026081001075813400_EUT083C19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2026081001075813400_EUT083C20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2026081001075813400_EUT083C23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"2026081001075813400_EUT083C24","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2026081001075813400_EUT083C25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban","volume":"58","author":"Moore","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026081001075813400_EUT083C26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2026081001075813400_EUT083C27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","author":"Mueck","journal-title":"Brit J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C28","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/eurheartj\/ehs167","article-title":"A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation","volume":"33","author":"Lahaye","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03256595","article-title":"Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics","volume":"9","author":"Stangier","year":"2009","journal-title":"Am J Cardiovasc Drugs, Drugs Dev Other Interv"},{"key":"2026081001075813400_EUT083C30","first-page":"2848","article-title":"The effect of quinidine and verapamil, P glycoprotein\/CYP3A4\/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics","volume":"107","author":"Mendell","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"A40 Abstract P062","key":"2026081001075813400_EUT083C31","article-title":"No interaction between rivaroxaban - a novel, oral direct factor Xa inhibitor - and atorvastatin","volume":"36","author":"Kubitza","year":"2008","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2026081001075813400_EUT083C32","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010393342","article-title":"Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin","author":"Stangier","journal-title":"J Clin Pharmacol"},{"issue":"702 (Abstract 11)","key":"2026081001075813400_EUT083C33","article-title":"No interaction between the novel, oral direct factor Xa inhibitor BAY 59\u20137939 and digoxin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"Hartter","year":"2012","journal-title":"Brit J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C35","first-page":"PP-WE-196","article-title":"Randomized, parallel group, warfarin control, multicenter phase II study evaluating safety of DU-176b in Japanese subjects with non-valvular atrial fibrillation (NVAF)","volume":"7","author":"Yasaka","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2026081001075813400_EUT083C36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C39","first-page":"139","article-title":"Adherence and dosing frequency of common medications for cardiovascular patients","volume":"18","author":"Bae","year":"2012","journal-title":"Am J Manag Care"},{"key":"2026081001075813400_EUT083C40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12325-012-0040-x","article-title":"Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients","volume":"29","author":"Laliberte","year":"2012","journal-title":"Adv Ther"},{"key":"2026081001075813400_EUT083C41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C42","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients With nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/CIRCULATIONAHA.112.147512","article-title":"\u2018R\u2019 for \u2018renal\u2019 and for \u2018risk\u2019: refining risk stratification for stroke in atrial fibrillation","volume":"127","author":"Camm","year":"2013","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026081001075813400_EUT083C46","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C47","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2026081001075813400_EUT083C49","first-page":"1124","article-title":"Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK\/PK-PD model","volume":"49","author":"Ridout","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Brit J Clin Pharmacol"},{"key":"2026081001075813400_EUT083C51","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026081001075813400_EUT083C52","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J Thromb Haemos"},{"key":"2026081001075813400_EUT083C53","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"2026081001075813400_EUT083C54","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1345\/aph.1R081","article-title":"Safe use of hemodialysis for dabigatran removal before cardiac surgery","volume":"46","author":"Wanek","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2026081001075813400_EUT083C55","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"2026081001075813400_EUT083C56","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J Thromb Haemos"},{"key":"2026081001075813400_EUT083C57","first-page":"A94","article-title":"Beriplex P\/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits","volume":"37","author":"Pragst","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2026081001075813400_EUT083C58","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemos"},{"key":"2026081001075813400_EUT083C59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"key":"2026081001075813400_EUT083C60","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemos"},{"key":"2026081001075813400_EUT083C62","first-page":"520","article-title":"Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. AHA Emerging Science Series, June 20, 2012","volume":"126","author":"Escolar","year":"2012","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C63","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate","volume":"93","author":"van Ryn","year":"2008","journal-title":"Haematologica"},{"key":"2026081001075813400_EUT083C64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C65","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis","volume":"104","author":"Sie","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"2026081001075813400_EUT083C66","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1365-2141.2003.04652.x","article-title":"Oral anticoagulation in surgical procedures: risks and recommendations","volume":"123","author":"Torn","year":"2003","journal-title":"Br J Haematol"},{"key":"2026081001075813400_EUT083C67","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jacc.2011.12.014","article-title":"Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry","volume":"59","author":"Lakkireddy","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026081001075813400_EUT083C68","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1253\/circj.CJ-12-0498","article-title":"Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation","volume":"76","author":"Kaseno","year":"2012","journal-title":"Circ J"},{"key":"2026081001075813400_EUT083C69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10840-012-9708-z","article-title":"A comparison of bleeding complications post-ablation between warfarin and dabigatran","volume":"35","author":"Snipelisky","year":"2012","journal-title":"J Interv Card Electrophysiol"},{"key":"2026081001075813400_EUT083C70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1540-8167.2011.02175.x","article-title":"The use of dabigatran immediately after atrial fibrillation ablation","volume":"23","author":"Winkle","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026081001075813400_EUT083C71","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2012.12.011","article-title":"Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation","author":"Kim","journal-title":"Heart Rhythm"},{"key":"2026081001075813400_EUT083C72","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/hrt.2007.134486","article-title":"Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation","volume":"94","author":"Lopes","year":"2008","journal-title":"Heart"},{"key":"2026081001075813400_EUT083C73","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/eurheartj\/ehp213","article-title":"Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial","volume":"30","author":"Lopes","year":"2009","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjmed.2009.09.015","article-title":"Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes","volume":"123","author":"Lopes","year":"2010","journal-title":"Am J Med"},{"key":"2026081001075813400_EUT083C75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026081001075813400_EUT083C76","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C77","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C78","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0735-1097(00)01118-9","article-title":"Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina","volume":"37","author":"The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026081001075813400_EUT083C79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction","volume":"350","author":"Coumadin Aspirin Reinfarction Study (CARS) Investigators","year":"1997","journal-title":"Lancet"},{"key":"2026081001075813400_EUT083C80","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"2026081001075813400_EUT083C81","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C82","doi-asserted-by":"publisher","author":"Dewilde","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"2026081001075813400_EUT083C83","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C84","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C85","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026081001075813400_EUT083C86","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026081001075813400_EUT083C87","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C88","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurheartj\/ehn099","article-title":"Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment","volume":"29","author":"Karjalainen","year":"2008","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C89","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial","volume":"50","author":"Mehta","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026081001075813400_EUT083C90","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"2026081001075813400_EUT083C91","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C92","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026081001075813400_EUT083C93","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"Brit Med J"},{"key":"2026081001075813400_EUT083C94","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C96","first-page":"686","article-title":"Apixaban and warfarin are associated with a low risk of stroke following cardioversion for AF: Results from the ARISTOTLE Trial","volume":"33","author":"Flaker","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001075813400_EUT083C97","doi-asserted-by":"crossref","DOI":"10.1161\/circ.126.suppl_21.A19281","article-title":"Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET-AF trial","volume":"126","author":"Piccini","year":"2012","journal-title":"Circulation"},{"key":"2026081001075813400_EUT083C98","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.STR.22.5.571","article-title":"Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment","volume":"22","author":"Radberg","year":"1991","journal-title":"Stroke"},{"key":"2026081001075813400_EUT083C99","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"Morgenstern","year":"2010","journal-title":"Stroke"},{"key":"2026081001075813400_EUT083C100","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"2026081001075813400_EUT083C101","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/15\/5\/625\/70586765\/europace_15_5_625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/15\/5\/625\/70586765\/europace_15_5_625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:12:02Z","timestamp":1786338722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/15\/5\/625\/675319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/eut083","relation":{},"ISSN":["1532-2092","1099-5129"],"issn-type":[{"value":"1532-2092","type":"electronic"},{"value":"1099-5129","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,5]]},"published":{"date-parts":[[2013,5,1]]}}}